Skip to content
value.today
Oncobiologics, Inc. logo

Oncobiologics, Inc.

Total raised
$52 M
3 rounds on record
Latest round
$6 M
Dec 2015
First round on record
Jun 2015
Today
Went public
See the company page

Oncobiologics, Inc. is listed today as Outlook Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 7 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Oncobiologics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2024$5 MPrivate placement after listing$2 to $10 million

Oncobiologics, Inc.: Private sale, Apr 2024

Investors in this round

1 investor had bought by the notice of Apr 16, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $13 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • C. Russell Trenary · Executive Officer, Director
  • Jeff Russell Evanson · Executive Officer
  • Lawrence A. Kenyon · Executive Officer, Director
  • Andong G. Huang · Director
  • Faisal G. Sukhtian · Director
  • Gerd G. Auffarth · Director
  • Julia A. Haller · Director
  • Julian G. Gangolli · Director
  • Kurt J. Hilzinger · Director
  • Randy H. Thurman · Director
  • Yezan H. Haddadin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total offering amount above includes the amount, if any, that the Issuer could receive if all of the issued Warrants were exercised.”

Signed by Lawrence Kenyon, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Apr 16, 2024. Read the notice at the SEC.

equity, optionsSEC
Mar 2024$60 MPrivate placement after listing$50 to $250 million

Oncobiologics, Inc.: Private sale, Mar 2024

Investors in this round

21 investors had bought by the notice of Mar 29, 2024: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$60 M of $159 M offered; $99 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$3,600,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • C. Russell Trenary · Executive Officer, Director
  • Jeff Russell Evanson · Executive Officer
  • Lawrence A. Kenyon · Executive Officer, Director
  • Andong G. Huang · Director
  • Faisal G. Sukhtian · Director
  • Gerd G. Auffarth · Director
  • Julia A. Haller · Director
  • Julian G. Gangolli · Director
  • Kurt J. Hilzinger · Director
  • Randy H. Thurman · Director
  • Yezan H. Haddadin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total offering amount above includes the amount, if any, that the Issuer could receive if all of the issued Warrants were exercised.”

Signed by Lawrence Kenyon, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Mar 29, 2024. Read the notice at the SEC.

equity, optionsSEC
Dec 2022$1 MPrivate placement after listingUnder $2 million

Oncobiologics, Inc.: Private sale, Dec 2022

Investors in this round

1 investor had bought by the notice of Jan 6, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • C. Russell Trenary · Executive Officer, Director
  • Lawrence A. Kenyon · Executive Officer, Director
  • Andong G. Huang · Director
  • Faisal G. Sukhtian · Director
  • Gerd G. Auffarth · Director
  • Julia A. Haller · Director
  • Julian G. Gangolli · Director
  • Kurt J. Hilzinger · Director
  • Randy H. Thurman · Director
  • Yezan H. Haddadin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Consists of warrants to purchase 515,755 shares of common stock at an exercise price of $2.00 per share issued to M.S. Howells & Co. as placement agent compensation in connection with a registered direct equity offering that is not reported here.”

Signed by Lawrence Kenyon, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Jan 6, 2023. Read the notice at the SEC.

optionsSEC
Feb 2021$4 MPrivate placement after listing$2 to $10 million

Oncobiologics, Inc.: Private sale, Feb 2021

Investors in this round

2 investors had bought by the notice of Feb 12, 2021: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Lawrence A. Kenyon · Executive Officer, Director
  • Andong G. Huang · Director
  • Faisal G. Sukhtian · Director
  • Gerd G. Auffarth · Director
  • Julian G. Gangolli · Director
  • Kurt J. Hilzinger · Director
  • Randy Thurman · Director
  • Yezan Haddadin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lawrence Kenyon, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 12, 2021. Read the notice at the SEC.

equitySEC
Jun 2020$16 MPrivate placement after listing$10 to $50 million

Oncobiologics, Inc.: Private sale, Jun 2020

Investors in this round

1 investor had bought by the notice of Jun 9, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeff G. Evanson · Executive Officer
  • Lawrence A. Kenyon · Executive Officer, Director
  • Terry G. Dagnon · Executive Officer
  • Faisal G. Sukhtian · Director
  • Gerd G. Auffarth · Director
  • Julian G. Gangolli · Director
  • Kurt J. Hilzinger · Director
  • Randy Thurman · Director
  • Yezan Haddadin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lawrence Kenyon, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 9, 2020. Read the notice at the SEC.

equitySEC
Feb 2020$8 MPrivate placement after listing$2 to $10 million

Oncobiologics, Inc.: Private sale, Feb 2020

Investors in this round

7 investors had bought by the notice of Mar 11, 2020: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$540,400
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeff G. Evanson · Executive Officer
  • Lawrence A. Kenyon · Executive Officer, Director
  • Terry G. Dagnon · Executive Officer
  • Faisal G. Sukhtian · Director
  • Kurt J. Hilzinger · Director
  • Randy Thurman · Director
  • Yezan Haddadin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · Newyork, New YorkSold in IL, NJ, NY

Remarks in the notice

  • On fees: “In addition, the placement agent was reimbursed $135,000 for expenses relating to the offering and received $77,200 for management fees.”
  • On the amounts: “Includes amounts receivable upon the exercise of warrants; such warrants have not yet been exercised”

Signed by Lawrence Kenyon, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 11, 2020. Read the notice at the SEC.

equity, optionsSEC
Sep 2017$3 MPrivate placement after listing$2 to $10 million

Oncobiologics, Inc.: Private sale, Sep 2017

Investors in this round

1 investor had bought by the notice of Sep 25, 2017: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $40 M offered; $37 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Series A Preferred Stock convertible into Common Stock and Warrants to purchase Common Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elizabeth A. Yamashita · Executive Officer
  • Kenneth M. Bahrt · Executive Officer
  • Lawrence C. Kenyon · Executive Officer
  • Pankaj Mohan · Executive Officer, Director
  • Scott A. Gangloff · Executive Officer
  • Stephen J. McAndrew · Executive Officer
  • Albert D. Dyrness · Director
  • Faisal G. Sukhtian · Director
  • Joe C. Thomas · Director
  • Kurt J. Hilzinger · Director
  • Scott G. Canute · Director
  • Todd C. Brady · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes proceeds of up to $15,075,000 upon future exercise of the Warrants.”

Signed by Pankaj Mohan, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 25, 2017. Read the notice at the SEC.

equity, optionsSEC
Dec 2015$6 MNo. 3$2 to $10 million

Oncobiologics, Inc.: Raise no. 3, Dec 2015

Investors in this round

11 investors had bought by the notice of Dec 23, 2015: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $50 M offered; $44 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Lawrence C. Kenyon · Executive Officer
  • Pankaj Mohan · Executive Officer, Director
  • Albert D. Dyrness · Director
  • Donald J. Griffith · Director
  • Kurt J. Hilzinger · Director
  • Robin C. Hoke · Director
  • Scott J. Canute · Director
  • Todd C. Brady · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Jefferies LLC (CRD 2347) · New York, New YorkSold in all US states
  • Cova Capital Partners LLC (CRD 109761) · Glen Head, New YorkSold in all US states

Signed by Pankaj Mohan, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 23, 2015. Read the notice at the SEC.

equitySEC
Sep 2015$14 MNo. 2$10 to $50 million

Oncobiologics, Inc.: Raise no. 2, Sep 2015

Investors in this round

4 investors had bought by the notice of Oct 13, 2015: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,348,686
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in New Jersey

People named in the notice

  • Lawrence Kenyon · Executive Officer
  • Pankaj Mohan · Executive Officer, Director
  • Donald Griffith · Director
  • Scott Canute · Director
  • Todd Brady · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Jefferies LLC (CRD 2347) · New York, New YorkSold in all US states
  • Citi Group Global Markets, Inc. (CRD 7059) · New York, New YorkSold in all US states

Signed by Pankaj Mohan, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 13, 2015. Read the notice at the SEC.

equitySEC
Jun 2015$31 MNo. 1$10 to $50 million

Oncobiologics, Inc.: Raise no. 1, Jun 2015

Investors in this round

7 investors had bought by the notice of Aug 10, 2015: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Oncobiologics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$31 M of $31 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,200,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in New Jersey

People named in the notice

  • Donald Griffith · Executive Officer, Director
  • Pankaj Mohan · Executive Officer, Director
  • Scott Canute · Director
  • Todd Brady · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Citi Group Global Markets, Inc. (CRD 7059) · New York, New YorkSold in all US states
  • Jefferies LLC (CRD 2347) · New York, New YorkSold in all US states

Signed by Pankaj Mohan, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 10, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Outlook Therapeutics, Inc., its revenue in fiscal 2025 came from these business segments: Development and commercialization of ONS-5010/LYTENAVA $1.41 million (100%).

    Annual report (SEC XBRL) · Sep 2025

  • Oncobiologics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2024).

    SEC Form D · Apr 2024

  • The industry group it chose in its notices: Other.

    SEC Form D · Apr 2024

Products and services#

No products or services of Oncobiologics, Inc. are on record.

Investors#

3 named in official filings. Open an investor to see everything it has backed.

Investors in Oncobiologics, Inc.
InvestorKindAmountRoundRoleSource
GMS Tenshi Holdings Pte. LtdCompanynot statednot statedHeld Series A preferred stock, 10% owner, director (Form 3, 2017)SEC Form 3
Scott A. CanutePersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2016)SEC Form 3
Todd C. BradyPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2016)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 11 investors.

Largest shareholders today

Institutions holding Outlook Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Oncobiologics, Inc.
NameRoleNamed in
C. Russell TrenaryExecutive officerApr 2024
Jeff Russell EvansonExecutive officerApr 2024
Lawrence A. KenyonExecutive officerApr 2024
Jeff G. EvansonExecutive officerJun 2020
Terry G. DagnonExecutive officerJun 2020
Elizabeth A. YamashitaExecutive officerSep 2017
Kenneth M. BahrtExecutive officerSep 2017
Lawrence C. KenyonExecutive officerSep 2017
Pankaj MohanExecutive officerSep 2017
Scott A. GangloffExecutive officerSep 2017
Stephen J. McAndrewExecutive officerSep 2017
Lawrence KenyonExecutive officerOct 2015
Donald GriffithExecutive officerAug 2015
Andong G. HuangDirectorApr 2024
C. Russell TrenaryDirectorApr 2024
Faisal G. SukhtianDirectorApr 2024
Gerd G. AuffarthDirectorApr 2024
Julia A. HallerDirectorApr 2024
Julian G. GangolliDirectorApr 2024
Kurt J. HilzingerDirectorApr 2024
Lawrence A. KenyonDirectorApr 2024
Randy H. ThurmanDirectorApr 2024
Yezan H. HaddadinDirectorApr 2024
Randy ThurmanDirectorFeb 2021
Yezan HaddadinDirectorFeb 2021
Albert D. DyrnessDirectorSep 2017
Joe C. ThomasDirectorSep 2017
Pankaj MohanDirectorSep 2017
Scott G. CanuteDirectorSep 2017
Todd C. BradyDirectorSep 2017
Donald J. GriffithDirectorDec 2015
Robin C. HokeDirectorDec 2015
Scott J. CanuteDirectorDec 2015
Donald GriffithDirectorOct 2015
Scott CanuteDirectorOct 2015
Todd BradyDirectorOct 2015

Went public since 2016. Its SEC number is that of a company listed on a stock exchange.